Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
Date:11/6/2009

ated in order to integrate the virus in the panoply of agents used for sarcoma treatment."

"These results are consistent with what we observed on an interim basis when we reported data on the first 16 patients back in June 2008," said Dr. Brad Thompson, President and CEO of Oncolytics. "It is encouraging that we are observing stable disease in a range of sarcomas and the clinical benefit is not isolated to any specific type."

A copy of the poster will be available on the Oncolytics website today.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at the CTOS meeting with respect to REOLYSIN; the Company's belief as to the potential of REOLYSIN as a cancer therapeutic; the Company's expectations as to the success of its research and development programs in 2009 and beyond, the Company's planned operations, the value of the additional patents and intellectual property; the Company's expectations related to the applications of the patented technology; the Company's expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs; and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the Company's actua
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014 The Global and China Diabetes ... the current state of the Diabetes Drug industry in ... overview of the industry, including definitions, applications and industry ... analysis are provided with a focus on history, developments, ... between the international and Chinese situation is also offered. ...
(Date:8/22/2014)... August 22, 2014 The AMA is ... its members in Alaska that Alaska Governor Sean Parnell ... 15, further defining public use of Unmanned Aircraft Systems ... Force. House Bill 255states that it is, “An Act ... captured by an unmanned aircraft system.” It defines State ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 “Our ... acknowledgement is a national disgrace. Furthermore, every governmental ... establishing the current, deplorable state of unorganized dysfunction ... great mistakes," to merely serve as a device ... extent of colossal failure(s) that have accumulated through ...
(Date:8/21/2014)... at the Institute for Molecular Medicine Finland (FIMM), ... developed a novel "man and machine" decision support ... aid was described in PLOS One ... based on computer vision algorithms similar to those ... of only the diagnostically most relevant areas. Tablet ...
Breaking Biology Technology:Diabetes Drugs Industry Growth Analysis in Global, China Regions Research Report Available at DeepResearchReports.com 2Diabetes Drugs Industry Growth Analysis in Global, China Regions Research Report Available at DeepResearchReports.com 3State of Alaska Signs Unmanned Aircraft Systems Bill 25 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2A novel 'man and machine' decision support system makes malaria diagnostics more effective 2
... Inc., a medical device,company that has developed a ... announced today that they have successfully raised $1.4,million ... Chief,Executive Officer, Clark Adams stated, "Valor,s Board and ... will be used to complete,clinical trials needed for ...
... 6 Halozyme Therapeutics, Inc.,(Nasdaq: HALO ), ... extracellular matrix for the drug delivery,endocrinology, oncology, and ... and nine months ended September 30, 2008., ... and I am,pleased with the initiation of our ...
... 6 NutraCea (OTC Bulletin Board:,NTRZ), a world ... and,technology announced today that it has appointed Olga ... Todd Crow, in accordance with,his previously announced intentions, ... a consulting and advisory capacity., Ms. Hernandez-Longan ...
Cached Biology Technology:Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 2Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 3Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 4Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 5Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 6Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 7Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 8NutraCea Appoints New Chief Financial Officer 2
(Date:8/22/2014)... French . NAIROBI (22 ... soils looming as a major threat to food security across ... the last five years, 1.7 million African farmers in 13 ... hectares and helped them double or even triple crop yields. ... in Africa (AGRA) focuses on intensive efforts initiated five years ...
(Date:8/22/2014)... 2014 Diabetes affects nearly 10 percent of ... diabetics: constant finger pricking to test blood glucose ... reports the development of a protein that could ... for diabetes patients. In the American Chemical Society,s ... shows off her "designer protein" that could eventually ...
(Date:8/22/2014)... MD FASEB MARC (Maximizing Access to Research Careers) ... FASEB Grant Writing Seminar & Practical Exercises Workshop which ... Bethesda, Maryland from August 25-26, 2014. These awards ... and research scientists from underrepresented groups in the the ... This year MARC conferred 11 awards totaling $20,350. , ...
Breaking Biology News(10 mins):Effort to confront Africa's soil health crisis helps millions of farmers triple yields 2Effort to confront Africa's soil health crisis helps millions of farmers triple yields 3Effort to confront Africa's soil health crisis helps millions of farmers triple yields 4
... light on the causes of Parkinson,s disease, researchers report that ... mitochondria. A shutdown in fuel can have devastating effects on ... energy despite making up only 2 percent of body weight. ... FDA approved drugs early on may prevent or delay the ...
... CAMBRIDGE, Mass. -- By creating a better way to ... with MIT,s Picower Institute for Learning and Memory and the ... synapse formation. These studies could also help further understanding of ... and Fragile X syndrome. The study will appear in the ...
... their dosages may be standardized, but not every patient ... personal genetic characteristics of individuals and populations can explain ... not another, so medical researchers are adopting the new ... lab is leading the way. Dr. Noam ...
Cached Biology News:In Parkinson's disease, brain cells abandon mitochondria, researchers report 2In Parkinson's disease, brain cells abandon mitochondria, researchers report 3MIT researchers develop a better way to see molecules at work in living brain cells 2An X-ray for your genes 2
... Set from different human fetal normal ... maybe available upon request. Customers ... the whole set, and pay 70% ... All Dr. P Set products are ...
... Steady gravity-fed delivery of buffer and ... perfusion. Rat version. In Vivo Manual ... gravity-fed delivery of buffer and fixative ... to setup, use and clean--Complete system ...
Mouse IL-31 RA Biotinylated Affinity Purified PAb...
... assay system offers the following ... for batch-processing systems, Long lasting ... microplates such as 384-well and ... storage conditions ( 2 - ...
Biology Products: